Química y Farmacia

For additional media
information, contact:
Arthur J. Shannon,
Vice President,Investor
Relations and
Communication
ajshannon@perrigo.com
269-686-1709(direct)
269-673-9128 (fax)

Ernest J. Schenk,
Manager, Investor Relations
and Communication
eschenk@perrigo.com
269-673-9212 (direct)
269-673-9128 (fax)


MÉXICO News		PERRIGO COMPANY News Perrigo To Present at Sidoti and Company 3rd Annual Emerging Growth Conference November 5, 2007 See Attachment Perrigo To Present at CIBC World Markets 18th Annual Healthcare Conference November 5, 2007 See Attachment Perrigo Reports Record Sales and Income for Fiscal 2008 First Quarter; Increases Full Year Guidance November 1, 2007 See Attachment Perrigo Announces That Dexcel's Settlement with AstraZenaca Allows OTC Omeprazole Launch Following Final FDA Approval November 1, 2007 See Attachment Perrigo Elevates Joseph C. Papa to Chairman of the Board October 31, 2007 See Attachment Perrigo Company Announces Dividend Increase October 30, 2007 See Attachment Perrigo Will Release First Quarter Fiscal 2008 Results on November 1, 2007 October 19, 2007 See Attachment Perrigo Confirms Filing for Generic Version of Mucinex® September 27, 2007 See Attachment Perrigo Presentation At Analyst Meeting Sept 18, 2007 September 18, 2007 See Attachment Perrigo To Host Analyst Meeting on September 18, 2007 September 14, 2007 See Attachment Perrigo Vice Chair Mori Arkin to Retire After 30 Years of Service September 13, 2007 See Attachment Perrigo Reports Record Sales for FY 2007 Full Year and Fourth Quarter August 23, 2007 See Attachment